Clinical Edge Journal Scan

High body weight and previous biologic use counter real-life guselkumab efficacy against plaque psoriasis

Key clinical point: This real-life study showed reduced efficacy of guselkumab for over 36 weeks in patients with moderate-to-severe chronic plaque psoriasis than previously reported, with body weight and exposure to biologics being the major predictors of response.

Major finding: At week 36, 67% of patients achieved Psoriasis Area Severity Index (PASI) 75 with heavier vs. low‐weight patients showing a decreased likelihood of achieving PASI 75 until week 4 (odds ratio [OR], 0.94; 95% confidence interval [CI], 0.88-0.99). Even at week 36, PASI 75 response rates were lower for patients exposed to 1 (OR, 0.07; 95% CI, 0.00-0.68) or more than 1 (OR, 0.00; 95% CI, 0.00-0.044) biologics than for biologic-naïve patients.

Study details: Findings are from a multicenter retrospective cohort study including 135 adult patients with moderate-to-severe chronic plaque psoriasis.

Disclosures: The study was supported by the Chang Gung Memorial Hospital and National Taiwan University Hospital, Hsin-Chu branch. Some of the authors declared serving as clinical trial participant or receiving speaker/consultancy honoraria from various sources.

Source: Hung YT et al. Ther Adv Chronic Dis. 2021 Sep 29. doi: 10.1177/20406223211046685 .

Recommended Reading

The Role of Inpatient Dermatology Consultations
MDedge Dermatology
Skin of Color in Preclinical Medical Education: A Cross-Institutional Comparison and A Call to Action
MDedge Dermatology
Study of biologics’ impact on psoriasis-to-PsA transition contradicts previous findings
MDedge Dermatology
Secukinumab hits mark against pediatric plaque psoriasis
MDedge Dermatology
Risankizumab shows excellent long-term PASI response in psoriasis under real-world conditions
MDedge Dermatology
Patient-reported outcome measures complement clinician-reported outcomes in psoriasis
MDedge Dermatology
Cal/BD foam gains ground among patients with plaque psoriasis
MDedge Dermatology
Smokers with periodontitis are at soaring risk for psoriasis
MDedge Dermatology
Guselkumab: A promising treatment option for moderate-to-severe plaque psoriasis
MDedge Dermatology
Occult blood in feces tied to increased risk for psoriasis
MDedge Dermatology